Literature DB >> 9583372

Dose- and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats.

P Bobek1, L Ozdín, S Galbavý.   

Abstract

The effect of the dose of oyster mushroom in the diet (1.0, 2.5, and 5.0%) and of the period of application (8, 16, 28, and 52 wk) on cholesterol accumulation in blood and body organs was studied in weanling male Wistar rats fed a diet containing 0.3% cholesterol. Reduction of cholesterol in serum and body organs was found to be dependent on the amount of dietary oyster mushroom administered. A negative correlation between the mushroom dose and cholesterol level was found after 8 and 28 wk of feeding (r=-0.9821 and -0.9803, respectively; P < 0.02 for both cases). The dose of 1% oyster mushroom did not affect cholesterol levels in serum or body organs. A significant reduction of cholesterol levels was observed in serum (31-46%) and liver (25-30%) at a dose of 5% of oyster mushroom for all periods. Reduced cholesterol content in very low-density lipoproteins (VLDL) was also observed at this level. The highest dose of oyster mushroom induced a decrease in conjugated diene levels in erythrocytes and an increase in the levels of reduced glutathione in the liver and stimulated the activities of catalase and glutathione peroxidase in the liver in the final period of the experiment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583372     DOI: 10.1016/s0899-9007(97)00471-1

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  7 in total

Review 1.  Effects of bioactive compounds from Pleurotus mushrooms on COVID-19 risk factors associated with the cardiovascular system.

Authors:  Eduardo Echer Dos Reis; Paulo Cavalheiro Schenkel; Marli Camassola
Journal:  J Integr Med       Date:  2022-07-11

2.  Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy.

Authors:  Donald I Abrams; Paul Couey; Starley B Shade; Mary Ellen Kelly; Nnemdi Kamanu-Elias; Paul Stamets
Journal:  BMC Complement Altern Med       Date:  2011-08-10       Impact factor: 3.659

Review 3.  Edible mushrooms: improving human health and promoting quality life.

Authors:  María Elena Valverde; Talía Hernández-Pérez; Octavio Paredes-López
Journal:  Int J Microbiol       Date:  2015-01-20

Review 4.  Edible Mushrooms as Novel Myco-Therapeutics: Effects on Lipid Level, Obesity and BMI.

Authors:  Faheem Mustafa; Hitesh Chopra; Atif Amin Baig; Satya Kumar Avula; Sony Kumari; Tapan Kumar Mohanta; Muthupandian Saravanan; Awdhesh Kumar Mishra; Nanaocha Sharma; Yugal Kishore Mohanta
Journal:  J Fungi (Basel)       Date:  2022-02-21

5.  Fatty acid compositions of six wild edible mushroom species.

Authors:  Pelin Günç Ergönül; Ilgaz Akata; Fatih Kalyoncu; Bülent Ergönül
Journal:  ScientificWorldJournal       Date:  2013-06-06

6.  Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs.

Authors:  A Berger; D Rein; E Kratky; I Monnard; H Hajjaj; I Meirim; C Piguet-Welsch; J Hauser; K Mace; P Niederberger
Journal:  Lipids Health Dis       Date:  2004-02-18       Impact factor: 3.876

7.  Anti-Inflammatory Activity of Pleurotus ostreatus, a Culinary Medicinal Mushroom, in Wistar Rats.

Authors:  W J A Banukie N Jayasuriya; Shiroma M Handunnetti; Chandanie A Wanigatunge; Gita H Fernando; D Thusitha U Abeytunga; T Sugandhika Suresh
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-05       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.